TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed price. Currency in USD
21.23
-0.20 (-0.93%)
At close: 4:01PM EDT

21.20 -0.03 (-0.14%)
After hours: 6:49PM EDT

Stock chart is not supported by your current browser
Previous close21.43
Open21.51
Bid21.20 x 1100
Ask21.33 x 1000
Day's range21.20 - 21.61
52-week range10.85 - 25.96
Volume8,303,949
Avg. volume12,051,584
Market cap21.618B
Beta (3Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-10.09
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2017-11-27
1y target est21.53
Trade prices are not sourced from all markets
  • How Novartis’s Innovative Medicines Business Performed in Q3
    Market Realist3 hours ago

    How Novartis’s Innovative Medicines Business Performed in Q3

    Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.

  • Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
    Market Realist6 hours ago

    Pfizer’s Third-Quarter Earnings: Analysts’ Estimates

    Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks3 days ago

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $21.45 in the latest trading session, marking a +0.85% move from the prior day.

  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist3 days ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • GlobeNewswire3 days ago

    New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • What Are Pfizer’s Revenue Drivers?
    Market Realist4 days ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
    Zacks5 days ago

    Regeneron's Dupixent Meets Goals in Nasal Polyps Studies

    Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.

  • A Financial Overview of Bausch Health in October
    Market Realist10 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • How Analysts View Bausch Health in October
    Market Realist10 days ago

    How Analysts View Bausch Health in October

    In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.

  • Investor Insights: Teva Pharmaceutical’s Valuation Multiples
    Market Realist11 days ago

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

  • Analysts Raised Their Recommendations on Teva Stock in October
    Market Realist11 days ago

    Analysts Raised Their Recommendations on Teva Stock in October

    Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.” The firm also raised its target price from $16 to $24 on October 1. The stock registered a rise of ~3.6% during premarket trading on the day. Teva has strong fundamentals that have been improving recently due in part to the more stable generics pricing environment in the United States.

  • Wall Street Analysts See Upside Potential of 3.9% in TEVA
    Market Realist11 days ago

    Wall Street Analysts See Upside Potential of 3.9% in TEVA

    Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.

  • Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
    Zacks11 days ago

    Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

    Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.

  • Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low
    Market Realist13 days ago

    Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low

    Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36. Also, Mylan has seen lower-than-expected sales from its biosimilar and complex products portfolio, which it’s increasingly focusing on in the wake of increasing generics competition and pricing pressures. Today, MYL stock fell ~2.7% during premarket trading.

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist13 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist17 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
    Market Realist18 days ago

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.

  • Mylan’s Recently Launched Generic Version of Ampyra
    Market Realist19 days ago

    Mylan’s Recently Launched Generic Version of Ampyra

    On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ (ACOR) Ampyra (dalfampridine), which is used for improvement in walking for adults who have multiple sclerosis. Mylan’s dalfampridine extended-release tablets are available in 10 mg tablets, similar to Acorda’s Ampyra. On September 21, MYL stock rose ~2.2% before closing up ~0.67% over the previous day’s closing price.

  • Why Teva Pharmaceutical Industries Ltd. (TEVA) is Poised to Beat Earnings Estimates Again
    Zacks20 days ago

    Why Teva Pharmaceutical Industries Ltd. (TEVA) is Poised to Beat Earnings Estimates Again

    Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist20 days ago

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.

  • Teva Pharmaceutical Stock Wins 2 Upgrades: What You Need to Know
    Motley Fool21 days ago

    Teva Pharmaceutical Stock Wins 2 Upgrades: What You Need to Know

    One analyst is particularly excited for the drugmaker's prospects.

  • Barrons.com21 days ago

    Teva Stock Is Struggling but 1 Analyst Says the Selloff Doesn’t Make Sense

    Teva Pharmaceutical stock has endured a selloff recently, but Goldman Sachs argues that the weakness is a buying opportunity.

  • Wall Street Expects 24% Upside Potential for MYL Stock
    Market Realist21 days ago

    Wall Street Expects 24% Upside Potential for MYL Stock

    According to the analysts surveyed by Reuters, the consensus target price for Mylan (MYL) stock is $46.61. This target price implies an ~24.0% return based on MYL’s September 25 closing price of $37.62.

  • GlaxoSmithKline’s Revenue Was Flat in Second Quarter
    Market Realist21 days ago

    GlaxoSmithKline’s Revenue Was Flat in Second Quarter

    GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018, nearly flat as compared to the second quarter of 2017. Revenues rose 4% at constant exchange rates, offset by a 4% negative impact of foreign exchange. The strengthening of the pound negatively affected overall revenues during the second quarter of 2018.

  • Teva's Worst Week of 2018 Prompts Goldman to Defend Stock
    Bloomberg21 days ago

    Teva's Worst Week of 2018 Prompts Goldman to Defend Stock

    Teva Pharmaceutical Industries Ltd had its worst week this year after two analysts cautioned on the generic drugmaker -- but Goldman Sachs is doubling down. Goldman analyst Jami Rubin added buy-rated Teva to her conviction list and called the sell-off “a head scratcher” but a good chance for investors to buy. Concerns arose after Bernstein warned on U.S. generics, Morgan Stanley lowered estimates on Teva for the rest of the year and a new Eli Lilly & Co. migraine drug was approved.